Related Experiment Videos

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations

M A Province1, M P Goetz2, H Brauch3

  • 1Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, Missouri, USA.

Clinical Pharmacology and Therapeutics
|September 25, 2013
PubMed

Insights

Cytochrome P450 2D6 (CYP2D6) poor metabolizer status predicted poorer outcomes in tamoxifen therapy for breast cancer patients under strict criteria. However, this association was not robust across different patient cohorts, necessitating further research.

Area of Science:

  • Pharmacogenomics
  • Oncology
  • Clinical Pharmacology

Background:

  • Tamoxifen is a widely used endocrine therapy for estrogen receptor-positive breast cancer.
  • The role of cytochrome P450 2D6 (CYP2D6) genetic status in tamoxifen efficacy remains controversial.
  • Inter-individual variability in tamoxifen response necessitates understanding factors influencing its clinical outcomes.

Purpose of the Study:

  • To investigate the association between CYP2D6 metabolizer status and clinical outcomes in tamoxifen-treated breast cancer patients.
  • To address the controversy surrounding CYP2D6 genotype and tamoxifen therapy effectiveness.
  • To evaluate the impact of strict eligibility criteria on the observed relationship.

Main Methods:

  • Meta-analysis of data from 4,973 patients across 12 international sites.
  • Inclusion of patients meeting strict criteria: postmenopausal, ER-positive breast cancer, 20 mg/day tamoxifen for 5 years.
  • Analysis of CYP2D6 poor metabolizer status and its association with invasive disease-free survival (IDFS).

Main Results:

  • Under strict eligibility criteria, CYP2D6 poor metabolizer status was significantly associated with poorer IDFS (HR=1.25, P=0.009).
  • This statistical significance was lost when less stringent criteria were applied (P=0.25 and P=0.38).
  • The findings highlight the sensitivity of the association to the definition of the patient cohort.

Conclusions:

  • CYP2D6 genotype may be a predictor of tamoxifen treatment outcomes, but only under specific patient selection criteria.
  • The lack of robustness across different inclusion criteria suggests that CYP2D6 status alone may not be a universal predictor.
  • Prospective studies are essential to definitively establish the clinical utility of CYP2D6 genotyping in guiding tamoxifen therapy.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...